Axtria, Inc.

Founded in 2010, chaired by Jassi Chadha as CEO, and based in New Jersey, US, Axtria, Inc. is a provider of cloud software and data analytics to the Life Science Industry and small and medium businesses (SMBs). The company serves over 100 life science companies across 75 countries globally. Axtria’s team is a blend of industry professionals, data scientists, business analysts, and technology experts where 75% are located in India.

In September 2025, Kedaara Capital acquired a stake in Axtria, Inc. from Sequoia Capital and other unspecified investors for USD 240 million. The company’s cloud-based platforms are Axtria DataMAx™ which is a cloud-based data management platform that integrates structured and unstructured data sources thereby enabling to onboard, manage and govern data sources for analytics and decision-making; and Axtria InsightsMAxTM offers data interlinking and industrialized analytics offering citizen data scientists, an AI-enabled analytics workbench where decision-makers can assemble analytics models of choice and drive insights. Additionally, the firm offers Axtria SalesIQTM, a cloud-based sales planning and operations platform that offers territory alignment and roaster management, call planning, incentive compensation management, and field analytics and reporting; and Axtria CustomerIQTM offering AI/MI-based analytics to provide an Omni customer experience thereby automating and optimizing the efficiency of sales and marketing channels.

Axtria generates revenue by offering its cloud software and data analytics solutions that help improve patient health and personalize the customer experience. Axtria’s solutions provide information management, cloud migration with DataMAx accelerators, Master Data Management (MDM), as well as consulting and managed services for specialty pharmacy, Next-Best-Actions (NBAs), advanced analytics for sales, marketing, patient and managed care, and analytics Center of Excellence (CoE). Axtria plans to use the funding to accelerate growth in AI-driven solutions for life sciences, expand global operations, strengthen its talent base and support an employee share buy-back program.